Total alkaloids of bulbus of <em>Fritillaria cirrhosa</em> alleviate bleomycin-induced inflammation and pulmonary fibrosis in rats by inhibiting TGF-β and NF-κB signaling pathway

Mingxin Pai; AGA Er-bu; Yexin Wu; Tse Wai Ming; Tse Kathy Wai Gaun; Bengui Ye

doi:10.29219/fnr.v67.10292

Mingxin Pai Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy Sichuan University, Chengdu, China
AGA Er-bu Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy Sichuan University, Chengdu, China; and School of Medicine, Tibet University, Lasa, China
Yexin Wu Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy Sichuan University, Chengdu, China
Tse Wai Ming Nin Jiom Medicine Manufactory (H.K.) Limited, Hong Kong, China
Tse Kathy Wai Gaun Nin Jiom Medicine Manufactory (H.K.) Limited, Hong Kong, China
Bengui Ye Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy Sichuan University, Chengdu, China; and School of Medicine, Tibet University, Lasa, China

DOI: https://doi.org/10.29219/fnr.v67.10292

Keywords: Fritillaria cirrhosa, total alkaloids, pulmonary fibrosis, inflammation, TGF-β, NF-κB

Abstract

Background: Bulbus of Fritillaria cirrhosa is a medicinal and edible plant that has the functions of clearing away heat and moisturizing the lungs, resolving phlegm, and relieving coughs. Its ethanol extract has been proven to have a therapeutic effect on lung diseases. Pulmonary fibrosis is a respiratory disease that forms scars in lung tissue, leading to severe respiratory problems. However, the therapeutic effect of total alkaloids of bulbus of Fritillaria cirrhosa (BFC-TA) on pulmonary fibrosis has not been confirmed.

Objective: This study aimed to investigate the therapeutic effect of total alkaloids of Fritillaria cirrhosa on pulmonary fibrosis rat model and explore its potential mechanism.

Design: The total alkaloids in the bulbus of Fritillaria cirrhosa were purified using cation exchange resin. The alkaloids contained in the BFC-TA were identified, and the concentration of alkaloids was determined by High Performance Liquid Chromatography-Diode Array Detector-Evaporative Light Scattering Detector (HPLC-DAD-ELSD). Bleomycin (BLM) (5.0 mg/kg) was instilled into the trachea of 60 rats to establish a pulmonary fibrosis model. After 7 days, BFC-TA (34.2, 68.4, and 136.8 mg/kg) was administered continuously for 21 days. During this period, the body weight changes of the rats were measured, the levels of hydroxyproline (HYP) and inflammatory factors were measured in the collected serum, and the histological analysis of the lung tissue was performed by staining technology. Western blotting and quantitative Polymerase Chain Reaction (qPCR) were used to assess the protein and gene composition of inflammation and transforming growth factor-β (TGF-β) signaling pathways.

Results: Nine main components (Peimisine, Imperialine-3-β-D-glucoside, Yibeinoside A, Imperialine, Peiminine, Isopeimine, Hupehenine, Delavinone, Ebeiedinone) were determined by HPLC-DAD-ELSD, and the contents of Peimisine, Imperialine-3-β-D-glucoside and Imperialine were determined. BFC-TA (34.2, 68.4, and 136.8 mg/kg) reduced the levels of pro-inflammatory factors, increased the levels of anti-inflammatory factors, dose-dependently improved the morphology of lung tissue. And during epithelial-mesenchymal transition process, BFC-TA dose-dependently reduced the expression of E-cadherin, dose-dependently increased the expression of Fibronectin. In addition, Western blot analysis and qPCR results showed that inhibiting NF-κB and TGF-β-related signaling pathways effectively slowed down the occurrence of BLM-induced pulmonary fibrosis in rats. And the therapeutic effect of BFC-TA (136.8 mg/kg) is better than that of pirfenidon (PFD) (150 mg/kg).

Conclusion: BFC-TA effectively alleviates the progression of the BLM-induced pulmonary fibrosis rat model by regulating the inflammatory response in the lungs and the expression of the TGF-β signaling pathway.

Downloads

Download data is not yet available.

References

1.
Chen D-Y, Zhang Z-Z, Li R-X, Chen J-Y, Dai X-F, Kong Z-Q, et al. Research progress on quality safety and analytical methods of Bulbus fritillaria. J Food Saf Qual 2021; 12: 9242–50. doi: 10.19812/j.cnki.jfsq11-5956/ts.2021.23.036

2.
Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China. Beijing: China Medical Science Press; 2020, pp. 38–9.

3.
Chen T, Zhong F, Yao C, Chen J, Xiang Y, Dong J, et al. A systematic review on traditional uses, sources, phytochemistry, pharmacology, pharmacokinetics, and toxicity of Fritillariae cirrhosae bulbus. Evid Based Complement Alternat Med 2020; 2020: 1536534. doi: 10.1155/2020/1536534

4.
Wang D, Chen X, Atanasov AG, Yi X, Wang S. Plant resource availability of medicinal Fritillaria species in traditional producing regions in Qinghai-Tibet Plateau. Front Pharmacol 2017; 8: 502. doi: 10.3389/fphar.2017.00502

5.
Lin G, Li P, Li SL, Chan SW. Chromatographic analysis of Fritillaria isosteroidal alkaloids, the active ingredients of Beimu, the antitussive traditional Chinese medicinal herb. J Chromatogr A 2001; 935(1–2): 321–38. doi: 10.1016/S0021-9673(01)01258-4

6.
Yuan S, Tse WM, Tse KWG, Xu FC, Xie HJ, Aga EB, et al. Ethanol extracts of bulbus of Fritillaria cirrhosa protects against pulmonary fibrosis in rats induced by bleomycin. J Funct Foods 2022; 97: 10. doi: 10.1016/j.jff.2022.105239

7.
Naccache JM, Montil M, Cadranel J, Cachanado M, Cottin V, Crestani B, et al. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP). BMC Pulm Med 2019; 19(1): 75. doi: 10.1186/s12890-019-0830-x

8.
Spagnolo P, Distler O, Ryerson CJ, Tzouvelekis A, Lee JS, Bonella F, et al. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis 2021; 80(2): 143–50. doi: 10.1136/annrheumdis-2020-217230

9.
Merkt W, Bueno M, Mora AL, Lagares D. Senotherapeutics: targeting senescence in idiopathic pulmonary fibrosis. Semin Cell Dev Biol 2020; 101: 104–10. doi: 10.1016/j.semcdb.2019.12.008

10.
Della Latta V, Cecchettini A, Del Ry S, Morales MA. Bleomycin in the setting of lung fibrosis induction: from biological mechanisms to counteractions. Pharmacol Res 2015; 97: 122–30. doi: 10.1016/j.phrs.2015.04.012

11.
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183(6): 788–824. doi: 10.1164/rccm.2009-040GL

12.
Bartram U, Speer C. The role of transforming growth factor beta in lung development and disease. Chest 2004; 125: 754–65. doi: 10.1378/chest.125.2.754

13.
Chen J, Lu J, Wang B, Zhang X, Huang Q, Yuan J, et al. Polysaccharides from Dendrobium officinale inhibit bleomycin-induced pulmonary fibrosis via the TGFbeta1-Smad2/3 axis. Int J Biol Macromol 2018; 118(Pt B): 2163–75. doi: 10.1016/j.ijbiomac.2018.07.056

14.
Spagnolo P, Maher TM, Richeldi L. Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy. Pharmacol Ther 2015; 152: 18–27. doi: 10.1016/j.pharmthera.2015.04.005

15.
Takehara K, Koga Y, Hachisu Y, Utsugi M, Sawada Y, Saito Y, et al. Differential discontinuation profiles between Pirfenidone and Nintedanib in patients with idiopathic pulmonary fibrosis. Cells 2022; 11(1): 143. doi: 10.3390/cells11010143

16.
Satsuma Y, Ikesue H, Kusuda K, Maeda M, Muroi N, Mori R, et al. Effectiveness of pharmacist-physician collaborative management for patients with idiopathic pulmonary fibrosis receiving pirfenidone. Front Pharmacol 2020; 11: 529654. doi: 10.3389/fphar.2020.529654

17.
Zhang S, Xie H, Aga E, Xie H, Xiong H, Zhao J, et al. Study on isosteroidal alkaloids from the bulbus of Fritillaria wabuensis. West China J Pharmaceut Sci 2022; 37(5): 481–4. doi: 10.13375/j.cnki.wcjps.2022.05.002

18.
Long Z, Guo Z, Acworth IN, Liu X, Jin Y, Liu X, et al. A non-derivative method for the quantitative analysis of isosteroidal alkaloids from Fritillaria by high performance liquid chromatography combined with charged aerosol detection. Talanta 2016; 151: 239–44. doi: 10.1016/j.talanta.2016.01.027

19.
Ma X, Liu A, Liu W, Wang Z, Chang N, Li S, et al. Analyze and identify peiminine target EGFR improve lung function and alleviate pulmonary fibrosis to prevent exacerbation of chronic obstructive pulmonary disease by Phosphoproteomics analysis. Front Pharmacol 2019; 10: 737. doi: 10.3389/fphar.2019.00737

20.
Wang D, Du Q, Li H, Wang S. The isosteroid alkaloid imperialine from bulbs of Fritillaria cirrhosa mitigates pulmonary functional and structural impairment and suppresses inflammatory response in a COPD-like rat model. Mediators Inflamm 2016; 2016: 1–17. doi: 10.1155/2016/4192483

21.
Dong Q, Yimamu H, Rozi P, Bakri M, Wali A, Abuduwaili A, et al. Fatty acids from Fritillaria pallidiflora and their biological activity. Chem Nat Compd 2018; 54(5): 959–60. doi: 10.1007/s10600-018-2521-x

22.
Mijiti Y, Rozi P, Waili A, Gao YH, Maksimov VV, Ziyavitdinov ZF, et al. Isolation of antimicrobial peptides from Fritillaria pallidiflora. Chem Nat Compd 2017; 53(6): 1144–7. doi: 10.1007/s10600-017-2219-5

23.
Tian R, Zhu Y, Yao J, Meng X, Wang J, Xie H, et al. NLRP3 participates in the regulation of EMT in bleomycin-induced pulmonary fibrosis. Exp Cell Res 2017; 357(2): 328–34. doi: 10.1016/j.yexcr.2017.05.028

24.
Jenkins RG, Moore BB, Chambers RC, Eickelberg O, Königshoff M, Kolb M, et al. An official American thoracic society workshop report: use of animal models for the preclinical assessment of potential therapies for pulmonary fibrosis. Am J Respir Cell Mol Biol 2017; 56(5): 667–79. doi: 10.1165/rcmb.2017-0096ST

25.
Pollard KM. Silica, silicosis, and autoimmunity. Front Immunol 2016; 7: 97. doi: 10.3389/fimmu.2016.00097

26.
Kou X, Sun Y, Li S, Bian W, Liu Z, Zhang D, et al. Pharmacology study of the multiple angiogenesis inhibitor RC28-E on anti-fibrosis in a chemically induced lung injury model. Biomolecules 2019; 9(11): 644. doi: 10.3390/biom9110644

27.
Xiao X, Senavirathna LK, Gou X, Huang C, Liang Y, Liu L. EZH2 enhances the differentiation of fibroblasts into myofibroblasts in idiopathic pulmonary fibrosis. Physiol Rep 2016; 4(17): e12915. doi: 10.14814/phy2.12915

28.
Chen P-Y, Qin L, Li G, Wang Z, Dahlman JE, Malagon-Lopez J, et al. Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis. Nat Metab 2019; 1(9): 912–26. doi: 10.1038/s42255-019-0102-3

29.
Huang F, Chen Y. Regulation of TGF-β receptor activity. Cell Biosci 2012; 2: 9. doi: 10.1186/2045-3701-2-9

30.
Hata A, Chen Y-G. TGF-β signaling from receptors to smads. Cold Spring Harb Perspect Biol 2016; 8(9): a022061. doi: 10.1101/cshperspect.a022061

31.
Xu F, Liu C, Zhou D, Zhang L. TGF-β/SMAD pathway and its regulation in hepatic fibrosis. J Histochemis Cytochemis 2016; 64(3): 157–67. doi: 10.1369/0022155415627681

32.
Heldin C-H, Moustakas A. Signaling receptors for TGF-β family members. Cold Spring Harb Perspect Biol 2016; 8(8): a022053. doi: 10.1101/cshperspect.a022053

33.
Tang Q, Xing C, Li M, Jia Q, Bo C, Zhang Z. Pirfenidone ameliorates pulmonary inflammation and fibrosis in a rat silicosis model by inhibiting macrophage polarization and JAK2/STAT3 signaling pathways. Ecotoxicol Environ Saf 2022; 244: 114066. doi: 10.1016/j.ecoenv.2022.114066

34.
O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 2015; 66(1): 311–28. doi: 10.1146/annurev-med-051113-024537

35.
Cai B, Cai J-p, Luo Y-l, Chen C, Zhang S. The specific roles of JAK/STAT signaling pathway in sepsis. Inflammation 2015; 38(4): 1599–608. doi: 10.1007/s10753-015-0135-z

36.
Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-κB signaling pathways. Nat Immunol 2011; 12(8): 695–708. doi: 10.1038/ni.2065

37.
Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther 2020; 5(1): 209. doi: 10.1038/s41392-020-00312-6

38.
Ma W-h, Li M, Ma H-f, Li W, Liu L, Yin Y, et al. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Life Sci 2020; 241: 117–39. doi: 10.1016/j.lfs.2019.117139

39.
Fan X, Yin X, Zhao Q, Yang Y. Hsa_circRNA_0045861 promotes renal injury in ureteropelvic junction obstruction via the microRNA-181d-5p/sirtuin 1 signaling axis. Ann Transl Med 2021; 9(20): 1571. doi: 10.21037/atm-21-5060

40.
Miyazono K. Transforming growth factor-β signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci 2009; 85(8): 314–23. doi: 10.2183/pjab.85.314

41.
Vancheri C, Gili E, Failla M, Mastruzzo C, Salinaro E, Lofurno D, et al. Bradykinin differentiates human lung fibroblasts to a myofibroblast phenotype via the B2 receptor. J Allergy Clin Immunol 2005; 116(6): 1242–8. doi: 10.1016/j.jaci.2005.09.025

42.
Karsdal MA, Detlefsen S, Daniels SJ, Nielsen MJ, Krag A, Schuppan D. Is the total amount as important as localization and type of collagen in liver fibrosis attributable to steatohepatitis? Hepatology 2019; 71(1): 346–51. doi: 10.1002/hep.30969

43.
Shinde AV, Humeres C, Frangogiannis NG. The role of α-smooth muscle actin in fibroblast-mediated matrix contraction and remodeling. Biochim Biophys Acta Mol Basis Dis 2017; 1863(1): 298–309. doi: 10.1016/j.bbadis.2016.11.006

44.
Mukhopadhyay P, Fan X, Zhang Q, Li S, Lv Y, Su H, et al. Attenuation of CCl4-induced hepatic fibrosis in mice by vaccinating against TGF-β1. PLoS One 2013; 8(12): e82190. doi: 10.1371/journal.pone.0082190

45.
Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev 2017; 26(146): 170057. doi: 10.1183/16000617.0057-2017

46.
Oltmanns U, Kahn N, Palmowski K, Träger A, Wenz H, Heussel CP, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German Tertiary Referral Center for interstitial lung diseases. Respiration 2014; 88(3): 199–207. doi: 10.1159/000363064

47.
Wijsenbeek MS, Grutters JC, Wuyts WA. Early experience of Pirfenidone in daily clinical practice in Belgium and the Netherlands: a retrospective cohort analysis. Adv Ther 2015; 32(7): 691–704. doi: 10.1007/s12325-015-0225-1

Total alkaloids of bulbus of Fritillaria cirrhosa alleviate bleomycin-induced inflammation and pulmonary fibrosis in rats by inhibiting TGF-β and NF-κB signaling pathway

Abstract

Downloads

References